Navigation Links
Amicus Therapeutics Announces Positive Progress of Three Lead Clinical Programs and General Outlook for 2009
Date:1/12/2009

anticipates ending 2009 with approximately $100 million in cash.

About Amicus Therapeutics

Amicus Therapeutics is a biopharmaceutical company developing novel, oral therapeutics known as pharmacological chaperones for the treatment of a range of human genetic diseases. Pharmacological chaperone technology involves the use of small molecules that selectively bind to and stabilize proteins in cells, leading to improved protein folding and trafficking, and increased activity. Amicus is initially targeting lysosomal storage disorders, which are severe, chronic genetic diseases with unmet medical needs. Amicus has completed Phase 2 clinical trials of Amigal for the treatment of Fabry disease and is conducting Phase 2 clinical trials of Plicera for the treatment of Gaucher disease and AT2220 for the treatment of Pompe disease.

Amicus has a strategic collaboration with Shire Human Genetic Therapies, Inc., a wholly-owned subsidiary of Shire Limited, to develop and commercialize Amicus' three lead pharmacological chaperone compounds for lysosomal storage disorders. Under the agreement, Shire received commercial rights outside of the United States. Amicus retains all U.S. rights.

About Shire plc

Shire's strategic goal is to become the leading specialty biopharmaceutical company that focuses on meeting the needs of the specialist physician. Shire focuses its business on attention deficit and hyperactivity disorder (ADHD), human genetic therapies (HGT) and gastrointestinal (GI) diseases as well as opportunities in other therapeutic areas to the extent they arise through acquisitions. Shire's in-licensing, merger and acquisition efforts are focused on products in specialist markets with strong intellectual property protection and global rights. Shire believes that a carefully selected and balanced portfolio of products with strategically aligned and relatively small-scale sales f
'/>"/>

SOURCE Amicus Therapeutics
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Amicus Therapeutics Announces Second Quarter 2008 Financial Results
2. Amicus Therapeutics Announces Successful Completion of End of Phase 2 Meeting With FDA for Amigal in Fabry Disease
3. Amicus Therapeutics Begins Phase 2 Clinical Trial of AT2220 in Pompe Disease
4. Amicus Therapeutics Presents Data from Clinical Ex Vivo Response Study and Phase 1 Studies of AT2220
5. Amicus Therapeutics to Present at the 26th Annual JPMorgan Healthcare Conference
6. Amicus Therapeutics Announces Positive Results From Two Phase 1 Clinical Studies of AT2220 for Pompe Disease
7. Amicus Therapeutics Announces Plans to Present Phase 1 Data for AT2220 for Pompe Disease
8. Amicus Therapeutics Announces Second Quarter 2007 Financial Results
9. Cara Therapeutics Initiates Phase II Proof-Of-Concept Trial of Novel Analgesic in Acute Post-Operative Pain
10. ExonHit Therapeutics Expands Strategic Collaboration With Allergan
11. Synvista Therapeutics Announces Published Data Demonstrating Elevation of Carboxymethyl-Lysine (CML) Is Associated with Decline in Renal Function and Arterial Stiffness in Older Adults
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/17/2014)... and SAN DIEGO , Dec. 17, ... PHG ; AEX: PHIA) and Volcano Corporation (NASDAQ: ... solutions for cardiovascular applications, today announced that they have entered ... will commence a tender offer to acquire all of the ... share, or a total equity purchase price of USD 1 ...
(Date:12/17/2014)... 17, 2014  Northstar Global Business Services, Inc. ... (DTC) has made their final decision and has ... Company,s stock effective December 15, 2014, and has ... depository and book entry transfer services. All deposit restrictions ... once again fully "DTC Eligible", and has resumed ...
(Date:12/17/2014)... , Dec. 17, 2014  ImmunoCellular Therapeutics, Ltd. ... Patent and Trademark Office (USPTO) has issued a ... dendritic cell-based immunotherapeutic vaccine targeting six tumor antigens ... of US Patent No. 8,871,211, which issued October ... by administering a dendritic cell composition comprising peptide ...
Breaking Medicine Technology:Philips to acquire Volcano to expand global leadership position in image-guided therapy market 2Philips to acquire Volcano to expand global leadership position in image-guided therapy market 3Philips to acquire Volcano to expand global leadership position in image-guided therapy market 4Philips to acquire Volcano to expand global leadership position in image-guided therapy market 5Philips to acquire Volcano to expand global leadership position in image-guided therapy market 6Philips to acquire Volcano to expand global leadership position in image-guided therapy market 7Philips to acquire Volcano to expand global leadership position in image-guided therapy market 8Northstar announces that the DTC chill on MDIN has been officially lifted 2Northstar announces that the DTC chill on MDIN has been officially lifted 3ImmunoCellular Therapeutics Announces Issuance of Key Patent For ICT-107 Cancer Vaccine 2
... ... research and biotechnology companies are testing 97 medicines and vaccines to ... report released today by the Pharmaceutical Research and Manufacturers of America ... - a global awareness campaign that originated at the 1988 World ...
... , XI,AN, China, Nov. ... a leading developer and producer,of plant extracts and pharmaceutical raw ... China, today reported that in its,third quarter, the company realized ... Revenues for the quarter ended Sept. 30, 2009 were $4,465,770, ...
Cached Medicine Technology:New Report Shows 97 Medicines and Vaccines Currently in Development for HIV/AIDS 2New Report Shows 97 Medicines and Vaccines Currently in Development for HIV/AIDS 3Huifeng Bio-Pharmaceutical Technology Reports 26% Quarterly Revenue Increase 2Huifeng Bio-Pharmaceutical Technology Reports 26% Quarterly Revenue Increase 3Huifeng Bio-Pharmaceutical Technology Reports 26% Quarterly Revenue Increase 4
(Date:12/22/2014)... 22, 2014 NAPW honors ... Woman of the Year. She is recognized with this ... most recognized networking organization of professional women in the ... Association of Professional Women is a vibrant networking community ... , Ms. Kreider is passionate and committed to best ...
(Date:12/21/2014)... 22, 2014 In this report, ... by power source, product, and application. The market, ... and pneumatic instruments. By product, the market covers ... segments. The handpieces market is further subdivided into ... coagulators, laparoscopic instruments, shavers, wire/pin drivers, and others. ...
(Date:12/21/2014)... Gables, FL (PRWEB) December 21, 2014 When ... head lice, who do they call? The new answer is ... Blvd, Coral Gables FL 33134, their newest treatment center will ... this pest quickly, conveniently and without the use of harmful ... Opening is scheduled for January 1, 2015. Like the company’s ...
(Date:12/21/2014)... (PRWEB) December 21, 2014 The number ... in a consolidated litigation underway in New Jersey, Bernstein ... total of 1,375 claims involving the birth control IUD ... These lawsuits were filed by women who allege spontaneous ... led to uterine perforations and other complications they were ...
(Date:12/21/2014)... (PRWEB) December 21, 2014 SCI ... of the issues and systemic barriers for disabled athletes ... Paratriathlon Champion. Scheidies has a condition called juvenile macular ... He describes how he adapted his athletic ambitions to ... his success in triathlon to pioneer the way for ...
Breaking Medicine News(10 mins):Health News:National Association of Professional Women Announces Cheryl A. Kreider, President / CEO of Kreider Health Solutions, LLC, a 2014 Professional Woman of the Year 2Health News:Global Powered Surgical Instruments Market Hit to $2.1 billion by 2019 - New Research Report by MarketsandMarkets 2Health News:Global Powered Surgical Instruments Market Hit to $2.1 billion by 2019 - New Research Report by MarketsandMarkets 3Health News:Global Powered Surgical Instruments Market Hit to $2.1 billion by 2019 - New Research Report by MarketsandMarkets 4Health News:All-Natural Florida Lice Removal Company Opens New Lice Treatment Salon In South Florida 2Health News:Mirena Lawsuits Approach 1,400 in Bergen County Litigation, Bernstein Liebhard LLP Reports 2Health News:Mirena Lawsuits Approach 1,400 in Bergen County Litigation, Bernstein Liebhard LLP Reports 3Health News:Disability in Sports on SCI TV with Triathlon World Champ Aaron Scheidies 2Health News:Disability in Sports on SCI TV with Triathlon World Champ Aaron Scheidies 3
... 24 (HealthDay News) -- Exclusive breast-feeding of infants for ... developing the itchy skin disorder known as eczema in ... infant receives only breast milk, with no additional food ... breast-feeding up to 6 months of age is recommended ...
... York, NY, August 24, 2011 Nearly three-quarters (72%) of people ... over the last two years said that they skipped needed ... cost, according to a new Commonwealth Fund report. The ... debt, compared to about half (49%) who lost jobs but ...
... , Governments in the UK, US and Canada are undermining ... smoking, a report by public health researchers says. The paper, ... argues that films with tobacco imagery should be ineligible for ... conflict with public health goals. Earlier research shows that ...
... News) -- Accidental exposure to highly toxic chemotherapy drugs ... a new study finds. Researchers surveyed 1,339 oncology ... infusion centers and found that nearly 17 percent said ... drugs. In the United States, about 84 percent ...
... HealthDay Reporter , TUESDAY, Aug. 23 (HealthDay News) ... jobless men in what,s been dubbed the "mancession" are ... support their working partners, a small study suggests. ... conducted intensive interviews of 19 recently unemployed men. She ...
... , TUESDAY, Aug. 23 (HealthDay News) -- A common ... worsen over time and may lead to an increased risk ... diastolic dysfunction, which often comes with advancing age, the heart,s ... and is accompanied by elevated filling pressures. The new ...
Cached Medicine News:Health News:Breast-Feeding Won't Prevent Kids' Eczema, Researchers Say 2Health News:Three quarters of those who have lost jobs and health insurance are skipping needed health care 2Health News:Three quarters of those who have lost jobs and health insurance are skipping needed health care 3Health News:Three quarters of those who have lost jobs and health insurance are skipping needed health care 4Health News:Government subsidies to the US film industry promote youth smoking, argue researchers 2Health News:Nurses at Risk for Accidental Exposure to Chemo Drugs: Study 2Health News:In Tough Times, Jobless Men Embrace Housework 2Health News:In Tough Times, Jobless Men Embrace Housework 3Health News:Common Heart Dysfunction Can Help Bring on Heart Failure 2
... CardioSEAL is a second generation device, ... was tested in over 700 patients beginning ... of leading pediatric cardiologists who perform these ... computer simulations, on the engineering bench, and ...
... YAG laser YC-1600 is a lightweight, compact, ... and clinical performance., ,Key Features, , ... Model ,Further weight reduction has been made ... office.,, Aiming Beam Rotation ,(360 degrees ...
... delivers a solid-state green laser ... and plugs into any standard ... and extreme portability, the unit ... Nidek Phaco Emulsification System CV-24000 ...
... is an effective angina relief ... poor targets. Because it is ... the CO2 Heart Laser 2 ... timely operative decisions to revascularize ...
Medicine Products: